MLM
LCTX icon

Mount Lucas Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Mount Lucas Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-19,431
Closed -$54K – 125
2017
Q2 		$54K Hold
19,431
– – 0.01% 138
2017
Q1 		$59K Buy
19,431
+6,286
+48% +$17.9K 0.01% 131
2016
Q4 		$42K Buy
13,145
+572
+5% +$1.76K 0.01% 138
2016
Q3 		$43K Buy
+12,573
New +$34.7K 0.01% 144

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Mount Lucas Management's LCTX Position: Q3 2017 in Review

Mount Lucas Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2017, closing a stake of 19,431 shares — an estimated $54K sold.

Mount Lucas Management first reported a position in LCTX in Q3 2016 and held it in 4 quarters. The position peaked at $59K in Q1 2017. 102 funds tracked by Wall St. Rank hold LCTX as of Q3 2017.

  • Mount Lucas Management reported no remaining Lineage Cell Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Mount Lucas Management sold 19,431 Lineage Cell Therapeutics shares in Q3 2017, an estimated $54K.
  • Mount Lucas Management first reported a position in Lineage Cell Therapeutics in Q3 2016 and held it in 4 quarters.
  • Mount Lucas Management's Lineage Cell Therapeutics position peaked at $59K in Q1 2017.
  • 102 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2017.

Based on Mount Lucas Management's 13F filing for Q3 2017, filed 14 Nov 2017.